|04-23-2019 11:00 AM CET - Health & Medicine||
Global Scleroderma Therapeutics Market 2019: Industry Analysis and Detailed Profiles of Top Industry Players Argentis Pharmaceuticals, LLC., F. Hoffmann-La Roche Ltd, AbbVie Inc., Pfizer Inc., Sanofi, ALLERGAN
Press release from: Data Bridge Market Research
Global Scleroderma Therapeutics market report is a comprehensive analysis on the study of Industry. This report helps focus you on the more important aspects of the market like what the market recent trends are. Scleroderma Therapeutics Market report includes historic data, present market trends, environment, technological innovation, upcoming technologies and the technical progress in the related industry. This study also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.
Global scleroderma therapeutics market is expected to reach USD 966.78 million by 2026 from USD 649.44 million in 2018, growing at a CAGR of 5.2% in the forecast period of 2019 to 2026.
Global Scleroderma Therapeutics Market By Type (Localized Scleroderma, Systemic Scleroderma), Treatment Type (Drug Treatment, Surgical Treatment, Therapy), End User (Hospital, Specialty Clinics, Homecare Settings, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2026– Industry Trends and Forecast to 2026
Download Free PDF Sample Copy of Report@ databridgemarketresearch.com/request-a-sample/?dbmr=globa...
Scleroderma is an auto-immune disease of unknown etiology and is characterized by fibrosis and microvascular injury in affected organs. In this disease, Raynaud’s phenomenon is an initial symptom which shows in puffiness of fingers. There are two types of scleroderma- localized scleroderma and limited scleroderma. Localized sclerosis shows plaques of fibrotic skin and subcutaneous tissue which further occurs as linear fibrotic bands on extremities such as skin and deeper tissue. There are two types of localized scleroderma which are morphea and linear scleroderma.
As per the studies carried out by researchers, it has been found that the disease occurs due to the changes in certain parameter in environment or changes in certain gene in human. The symptoms involves in this disease is abnormalities on the skin, painful joints, morning stiffness, fatigue, and/or weight loss and many others.
There is no drug or treatment available to treat scleroderma but there are certain drugs available which can be used in treating the disease associated to scleroderma such as kidney disease, Heartburn (acid reflux), Raynaud’s phenomenon and others. Some of them are aspirin, naproxen, ibuprofen and many others.
Competitive Analysis: Global Scleroderma Therapeutics Market
Some of the prominent participants operating in this market are Argentis Pharmaceuticals, LLC., F. Hoffmann-La Roche Ltd, AbbVie Inc., Pfizer Inc., Sanofi, ALLERGAN, viDA Therapeutics Inc., Novartis AG, Active Biotech AB., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Johnson & Johnson Services, Inc., AstraZeneca, Daval International Limited and others.
To Avail 10% Discount On This Report Mail Us on :- email@example.com
Global scleroderma therapeutics market is segmented into three notable segments such as type, treatment type, end user.
• On the basis of type, the market is segmented into localized scleroderma and systemic scleroderma. Localized scleroderma is further segmented into morphea and linear scleroderma. Systemic scleroderma is further segmented into limited cutaneous systemic sclerosis or CREST syndrome and diffuse systemic sclerosis. In 2019 systemic scleroderma segment is growing at the highest CAGR in the forecast period of 2019 to 2026.
• On the basis of treatment type, the market is segmented into drug treatment, surgery treatment and therapy. Drug treatment is further segmented into anti-inflammatory drugs, immunosuppressants, corticosteroids, H2 blockers, chelating agents, proton pump inhibitors, PDE5 inhibitors, prostacyclin analogues, ACE inhibitors, endothelin receptor antagonists, calcium channel blockers and others. Therapy is further segmented into physical therapy, ultraviolet light therapy and others. In 2019, anti-inflammatory drugs segment is growing at the highest CAGR in the forecast period of 2019 to 2026.
• On the basis of end user, the market is segmented into hospital, speciality clinics, homecare settings and others. In 2019, hospital segment is growing at the highest CAGR of in the forecast period of 2019 to 2026.
To Inquire before Buy Report @ databridgemarketresearch.com/inquire-before-buying/?dbmr=...
Note: If you have any special requirements, please let us know and we will offer you the report as you want.
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data Bridge Market Research
This release was published on openPR.
News-ID: 1713880 • Views: 350More releases